Omnicef: Effective Treatment for Bacterial Infections
| Product dosage: 300mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $4.49 | $134.60 (0%) | 🛒 Add to cart |
| 60 | $3.68 | $269.20 $220.98 (18%) | 🛒 Add to cart |
| 90 | $3.40 | $403.79 $306.36 (24%) | 🛒 Add to cart |
| 120 | $3.27 | $538.39 $392.74 (27%) | 🛒 Add to cart |
| 180 | $3.13
Best per pill | $807.59 $563.50 (30%) | 🛒 Add to cart |
Synonyms | |||
Omnicef (cefdinir) is a broad-spectrum, third-generation cephalosporin antibiotic indicated for the treatment of mild to moderate bacterial infections in both adults and pediatric patients. Its advanced formulation targets a wide range of gram-positive and gram-negative pathogens, making it a versatile choice for clinicians managing common community-acquired infections. With proven efficacy, convenient once- or twice-daily dosing, and a generally favorable tolerability profile, Omnicef remains a trusted option in outpatient antimicrobial therapy.
Features
- Active ingredient: cefdinir (300 mg per capsule; 125 mg/5 mL and 250 mg/5 mL oral suspension)
- Broad-spectrum activity against common respiratory and skin pathogens
- Third-generation cephalosporin with enhanced stability against beta-lactamases
- Available in both capsule and pleasant-tasting oral suspension formulations
- Dosing flexibility with once- or twice-daily administration
Benefits
- Effectively eradicates susceptible bacteria causing respiratory, skin, and soft tissue infections
- Convenient dosing schedule supports patient adherence and completion of therapy
- Generally well-tolerated with a lower incidence of severe adverse effects compared to some alternative antibiotics
- Suitable for pediatric use with weight-based dosing and palatable suspension
- Rapid absorption and distribution to infection sites for prompt therapeutic effect
Common use
Omnicef is commonly prescribed for the treatment of community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute bacterial sinusitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections. It demonstrates particular efficacy against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pyogenes, and Staphylococcus aureus (methicillin-susceptible strains only).
Dosage and direction
Adults and adolescents (13 years and older): 300 mg every 12 hours or 600 mg once daily for 5-10 days depending on infection type and severity.
Pediatric patients (6 months to 12 years): 7 mg/kg every 12 hours or 14 mg/kg once daily for 5-10 days.
The oral suspension should be shaken well before each use. Omnicef may be taken with or without food, though administration with food may minimize gastrointestinal discomfort. Complete the full course of therapy even if symptoms improve earlier.
Precautions
Patients with known hypersensitivity to cephalosporins should use Omnicef with caution due to potential cross-reactivity with penicillin-allergic individuals (occurring in approximately 10% of such patients). Use with caution in patients with renal impairment (creatinine clearance <30 mL/min requires dosage adjustment). May cause Clostridium difficile-associated diarrhea, ranging from mild to life-threatening colitis. Monitor for superinfection and development of drug-resistant bacteria.
Contraindications
Omnicef is contraindicated in patients with known hypersensitivity to cefdinir or other cephalosporin antibiotics. Avoid use in patients with a history of severe allergic reactions (anaphylaxis) to any beta-lactam antibiotics. The oral suspension contains sucrose and is contraindicated in patients with hereditary fructose intolerance.
Possible side effect
Common adverse reactions (≥1%) include diarrhea (up to 8%), nausea (3%), vaginal moniliasis (3%), headache (2%), and abdominal pain (1%). Less frequent side effects include rash, vomiting, dyspepsia, flatulence, and dizziness. Serious but rare side effects include pseudomembranous colitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, and anaphylaxis. Discontinue immediately if severe reactions occur.
Drug interaction
Antacids containing magnesium or aluminum and iron supplements may significantly reduce cefdinir absorption—administer Omnicef at least 2 hours before or after these products. Probenecid may increase and prolong cefdinir blood levels. No clinically significant interactions with warfarin have been observed, though monitoring is recommended during concomitant therapy.
Missed dose
If a dose is missed, take it as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed one. Maintain regular dosing intervals to ensure consistent antibiotic levels.
Overdose
Symptoms of overdose may include nausea, vomiting, epigastric distress, and diarrhea. Gastric lavage may be beneficial if performed shortly after ingestion. Cefdinir is not removed by hemodialysis. Provide supportive care and maintain hydration. There is no specific antidote for cefdinir overdose.
Storage
Store capsules at controlled room temperature (20-25°C or 68-77°F) in a tightly closed container. Keep oral suspension refrigerated (2-8°C or 36-46°F) and discard any unused portion after 10 days. Keep all medications out of reach of children and protected from light and moisture.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Always consult a healthcare provider for diagnosis and appropriate treatment recommendations. The prescribing physician should review the complete prescribing information before initiating therapy.
Reviews
Clinical studies demonstrate Omnicef’s efficacy with clinical cure rates of 85-94% for respiratory tract infections and 86-92% for skin infections. Physicians report satisfaction with its spectrum of activity, dosing convenience, and generally favorable side effect profile. Patients appreciate the once-daily option and the palatability of the suspension formulation in pediatric populations.